Citadel Advisors’s Thermo Fisher Scientific TMO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$144M Buy
293,600
+6,200
+2% +$3.36M 0.02% 607
2025
Q4
$167M Sell
287,400
-57,200
-17% -$32.3M 0.03% 572
2025
Q3
$167M Sell
344,600
-15,000
-4% -$6.98M 0.03% 556
2025
Q2
$146M Buy
359,600
+75,000
+26% +$31.4M 0.03% 536
2025
Q1
$142M Buy
284,600
+20,600
+8% +$11.2M 0.03% 506
2024
Q4
$137M Sell
264,000
-47,300
-15% -$26M 0.02% 563
2024
Q3
$193M Buy
311,300
+54,900
+21% +$32.5M 0.04% 376
2024
Q2
$142M Buy
256,400
+18,300
+8% +$10.5M 0.03% 496
2024
Q1
$138M Sell
238,100
-200,800
-46% -$113M 0.03% 532
2023
Q4
$233M Sell
438,900
-31,400
-7% -$15.2M 0.05% 293
2023
Q3
$238M Sell
470,300
-91,100
-16% -$48.5M 0.05% 261
2023
Q2
$293M Buy
561,400
+137,600
+32% +$74.3M 0.06% 182
2023
Q1
$244M Buy
423,800
+2,000
+0.5% +$1.13M 0.05% 247
2022
Q4
$232M Sell
421,800
-406,200
-49% -$215M 0.05% 286
2022
Q3
$420M Buy
828,000
+480,100
+138% +$269M 0.1% 120
2022
Q2
$189M Sell
347,900
-32,200
-8% -$17.7M 0.05% 292
2022
Q1
$225M Sell
380,100
-39,700
-9% -$22.8M 0.05% 301
2021
Q4
$280M Sell
419,800
-2,800
-0.7% -$1.75M 0.06% 232
2021
Q3
$241M Buy
422,600
+126,300
+43% +$69.3M 0.05% 282
2021
Q2
$149M Buy
296,300
+149,300
+102% +$70.4M 0.03% 465
2021
Q1
$67.1M Sell
147,000
-233,200
-61% -$111M 0.02% 813
2020
Q4
$177M Buy
380,200
+155,000
+69% +$72.7M 0.05% 301
2020
Q3
$99.4M Buy
225,200
+54,600
+32% +$22.6M 0.03% 469
2020
Q2
$61.8M Sell
170,600
-27,400
-14% -$9.18M 0.02% 665
2020
Q1
$56.2M Buy
198,000
+1,600
+0.8% +$505K 0.03% 588
2019
Q4
$63.8M Buy
196,400
+7,600
+4% +$2.3M 0.03% 639
2019
Q3
$55M Buy
188,800
+800
+0.4% +$229K 0.03% 700
2019
Q2
$55.2M Buy
188,000
+88,800
+90% +$24.5M 0.03% 673
2019
Q1
$27.2M Sell
99,200
-28,800
-23% -$7.17M 0.01% 1088
2018
Q4
$28.6M Sell
128,000
-12,000
-9% -$2.82M 0.02% 961
2018
Q3
$34.2M Buy
140,000
+66,900
+92% +$15.4M 0.02% 990
2018
Q2
$15.1M Sell
73,100
-12,800
-15% -$2.72M 0.01% 1556
2018
Q1
$17.7M Buy
85,900
+15,900
+23% +$3.34M 0.01% 1231
2017
Q4
$13.3M Sell
70,000
-4,300
-6% -$824K 0.01% 1451
2017
Q3
$14.1M Buy
74,300
+2,600
+4% +$471K 0.01% 1319
2017
Q2
$12.5M Buy
71,700
+700
+1% +$118K 0.01% 1286
2017
Q1
$10.9M Sell
71,000
-9,300
-12% -$1.42M 0.01% 1376
2016
Q4
$11.3M Sell
80,300
-21,300
-21% -$3.14M 0.01% 1262
2016
Q3
$16.2M Buy
101,600
+32,900
+48% +$5.07M 0.02% 1001
2016
Q2
$10.2M Sell
68,700
-30,700
-31% -$4.53M 0.01% 1237
2016
Q1
$14.1M Buy
99,400
+6,500
+7% +$871K 0.02% 965
2015
Q4
$13.2M Buy
92,900
+34,800
+60% +$4.64M 0.01% 1081
2015
Q3
$7.1M Sell
58,100
-17,000
-23% -$2.21M 0.01% 1599
2015
Q2
$9.74M Buy
75,100
+14,800
+25% +$1.93M 0.01% 1495
2015
Q1
$8.1M Buy
60,300
+16,700
+38% +$2.15M 0.01% 1622
2014
Q4
$5.46M Sell
43,600
-16,500
-27% -$2.01M 0.01% 1900
2014
Q3
$7.31M Buy
60,100
+24,900
+71% +$3.03M 0.01% 1640
2014
Q2
$4.15M Sell
35,200
-18,400
-34% -$2.17M ﹤0.01% 2004
2014
Q1
$6.45M Buy
53,600
+36,200
+208% +$4.3M 0.01% 1565
2013
Q4
$1.94M Sell
17,400
-14,700
-46% -$1.46M ﹤0.01% 2585
2013
Q3
$2.96M Sell
32,100
-15,600
-33% -$1.41M ﹤0.01% 2035
2013
Q2
$4.04M Buy
+47,700
New +$3.97M 0.01% 1767

Other funds holding TMO

Citadel Advisors's TMO Position: Q1 2026 in Review

Citadel Advisors increased its Thermo Fisher Scientific (TMO) stake by 25% in Q1 2026, buying an estimated $94.5M and bringing the position to 864,489 shares worth $425M. The position accounts for 0.07% of the portfolio, ranked #216.

Citadel Advisors first reported a position in TMO in Q2 2013 and has held it in 50 quarters since. The position peaked at $543M in Q2 2024. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.

  • Citadel Advisors held 864,489 shares of Thermo Fisher Scientific worth $425M as of Q1 2026.
  • Citadel Advisors bought 174,084 Thermo Fisher Scientific shares in Q1 2026, an estimated $94.5M.
  • Thermo Fisher Scientific made up 0.07% of Citadel Advisors's portfolio in Q1 2026, its #216 holding.
  • Citadel Advisors first reported a position in Thermo Fisher Scientific in Q2 2013 and has held it in 50 quarters since.
  • Citadel Advisors's Thermo Fisher Scientific position peaked at $543M in Q2 2024.
  • 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.